Join
Live feed
·
PRReleasevia Quantisnow
Coya Therapeutics Inc. logo

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

ByQuantisnow·Wall Street's wire, on your screen.
COYA· Coya Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track COYA (Coya Therapeutics Inc.) and more on Quantisnow.